From Rebound to Recovery: Managing the Alpha-2 Agonist Withdrawal in Outpatient Settings
Link to Register: https://zoom.us/webinar/register/WN_gD9l1c9bQF6aXUZlWJT0Bw
Description:
The continued presence of medetomidine in the drug supply has necessitated changes to withdrawal management for patients who have opioid use disorder across the healthcare continuum. Patients seeking to start medications for opioid use disorder or who are returning to outpatient settings from inpatient care for opioid and medetomidine withdrawal need continued follow up to safely taper medications.
This case-based panel discussion will explore the current understanding of treating medetomidine withdrawal in outpatient settings and discuss how to troubleshoot what to do for vital sign abnormalities, medication management if a patient returns to use and how to support patients who require hospital admission
Objectives:
- Describe medication management of patients transitioning from inpatient settings who require tapering of medications used to treat medetomidine withdrawal.
- Describe the clinical factors and considerations in managing medetomidine withdrawal in outpatient settings.
Faculty:
- Judy Chertok, MD, FAAFP
- Penn Medicine
- Associate Professor of Clinical Family Medicine and Community Health
- Program Director, Fellowship in Addiction Medicine
- Director of Addiction Medicine, Department of Family Medicine
- Rachael Truchil, MD, MPH
- Penn Medicine
- Associate Professor, Clinical Family Medicine (General Internal Medicine)
- Director of Addiction Medicine, Division of General Internal Medicine
- Keriann Shalvoy, MD, MPH, PMH-C
- Thomas Jefferson University Sydney-Kimmel Medical College
- Clinical Assistant Professor of Psychiatry
- Associate Program Director, Addiction Psychiatry Fellowship
- Associate Medical Director, Center for Community for Substance Abuse Programs
Accreditation: CME, Nursing, Pharmacy